IP Library Granted Patent US 7,261,544
Granted Patent B2
US 7,261,544 · App. 10/851,688 · Granted Aug 28, 2007

Methods for producing preparations of recombinant AAV virions substantially free of empty capsids

Assignee: Genzyme Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,261,544
App. No.
10/851,688
Granted
Aug 28, 2007
Kind
B2
Abstract

Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.

Claims (40)

1. A method for purifying AAV vector particles from an AAV preparation comprising AAV vector particles and AAV empty capsids, to provide an AAV product substantially free of AAV empty capsids, said method comprising:

(a) providing a host cell comprising AAV vector particles;

(b) lysing said host cell to obtain a crude cell lysate comprising AAV vector particles and AAV empty capsids;

(c) applying said crude cell lysate to a cation exchange chromatograhphy column under conditions whereby said AAV vector particles and said AAV empty capsids bind the column;

(d) eluting said AAV vector particles and said AAV empty capsids under non-separating conditions to provide an AAV preparation comprising AAV vector particles and AAV empty capsids;

(e) applying the AAV preparation from (d) to an anion exchange chromatography column under conditions whereby said AAV vector particles and said AAV empty capsids bind the column;

(f) adding a salt buffer to the column from (e) under conditions whereby AAV empty capsids are eluted and AAV vector particles remain bound to the column;

(g) adding a buffer with a greater salt concentration relative to the buffer added in (f) to the column from (f) under conditions whereby AAV vector particles are eluted;

(h) collecting eluted fractions from (g) that comprise AAV vector particles to provide an AAV product substantially free of AAV empty capsids.

2. The method of claim 1 , further comprising:

(i) applying the AAV preparation from (h) to a second anion exchange chromatography column under conditions whereby said AAV vector particles and said AAV empty capsids, if present, bind the column;

(j) adding a salt buffer to the column from (i) under conditions whereby AAV empty capsids are eluted and AAV vector particles remain bound to the column;

(k) adding a buffer with a greater salt concentration relative to the buffer added in (j) to the column from (j) under conditions whereby AAV vector particles are eluted;

(l) collecting eluted fractions from (k) that comprise AAV vector particles to provide an AAV product substantially free of AAV empty capsids.

3. The method of claim 1 , further comprising:

(i) applying the AAV preparation from (h) to a second cation exchange chromatography column under conditions whereby said AAV vector particles and said AAV empty capsids bind the column;

(j) adding a salt buffer to the column from (i) under conditions whereby AAV vector particles are eluted and AAV empty capsids remain bound to the column; and

(k) collecting eluted fractions from (j) that comprise AAV vector particles to provide an AAV product substantially free of AAV empty capsids.

4. The method of claim 1 , wherein AAV vector particles are present in said AAV product in an amount of at least 75%.

5. The method of claim 1 , wherein AAV vector particles are present in said AAV product in an amount of at least 85%.

6. The method of claim 1 , wherein AAV vector particles are present in said AAV product in an amount of at least 90%.

7. The method of claim 1 , wherein said AAV vector particles are from AAV-2.

8. The method of claim 1 , wherein said AAV vector particles are from AAV-5.

9. A method for purifying AAV vector particles from an AAV preparation comprising AAV vector particles and AAV empty capsids, to provide an AAV product substantially free of AAV empty capsids, said method comprising:

(a) providing a host cell comprising AAV vector particles;

(b) lysing said host cell to obtain a crude cell lysate comprising AAV vector particles and AAV empty capsids;

(c) clarifying said crude cell lysate to provide a clarified cell lysate;

(d) applying said clarified cell lysate to a first cation exchange chromatograhphy column comprising a matrix with the functional ligand R—SO 3 —, under conditions whereby said AAV vector particles and said AAV empty capsids bind the column;

(e) eluting said AAV vector particles and said AAV empty capsids under non-separating conditions to provide an AAV preparation comprising AAV vector particles and AAV empty capsids;

(f) applying the AAV preparation from (e) to a second cation exchange chromatography column under conditions whereby said AAV vector particles and said AAV empty capsids bind the column;

(g) adding a low salt buffer to the column from (f) under conditions whereby AAV vector particles are eluted and AAV empty capsids remain bound to the column;

(h) collecting eluted fractions from (g) that comprise AAV vector particles; (i) applying the fractions from step (h) to an anion exchange chromatography column under conditions whereby said AAV vector particles and AAV empty capsids, if present, bind the column;

(j) adding a low salt buffer to the column from (i) under conditions whereby AAV empty capsids are eluted and AAV vector particles remain bound to the column;

(k) adding a high salt buffer to the column from (j) under conditions whereby AAV vector particles are eluted; and

(l) collecting eluted fractions from (k) that comprise AAV vector particles to provide an AAV product substantially free of AAV empty capsids.

10. The method of claim 9 , wherein AAV vector particles are present in said AAV product in an amount of at least 75%.

11. The method of claim 9 , wherein AAV vector particles are present in said AAV product in an amount of at least 85%.

12. The method of claim 9 , wherein AAV vector particles are present in said AAV product in an amount of at least 90%.

13. The method of claim 9 , wherein said AAV vector particles are derived from AAV-2.

14. The method of claim 9 , wherein said AAV vector particles are derived from AAV-5.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2007
From: AVIGEN, INC.
To: GENZYME CORPORATION
Reel/Frame 019881/0470 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 12, 2004
From: QU, GUANG; WRIGHT, JOHN FRASER
To: AVIGEN, INC.
Reel/Frame 015238/0603 →
Continuity (3)
Provisional Application 6054975600 · Mar 2, 2004
Provisional Application 6047238400 · May 21, 2003
Related Publication 20050042740A1 · Feb 24, 2005